FUKOKU MUTUAL LIFE INSURANCE Co held its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 360 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Regeneron Pharmaceuticals were worth $177,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Victory Capital Management Inc. increased its stake in Regeneron Pharmaceuticals by 24.2% during the 1st quarter. Victory Capital Management Inc. now owns 3,567 shares of the biopharmaceutical company’s stock valued at $1,382,000 after buying an additional 694 shares during the period. Blair William & Co. IL raised its position in shares of Regeneron Pharmaceuticals by 16.1% during the 1st quarter. Blair William & Co. IL now owns 1,634 shares of the biopharmaceutical company’s stock worth $612,000 after buying an additional 226 shares in the last quarter. Artisan Partners Limited Partnership lifted its stake in shares of Regeneron Pharmaceuticals by 2.2% in the 1st quarter. Artisan Partners Limited Partnership now owns 1,933,228 shares of the biopharmaceutical company’s stock worth $749,145,000 after acquiring an additional 41,630 shares during the period. Comerica Securities Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $213,000. Finally, Alliancebernstein L.P. lifted its stake in shares of Regeneron Pharmaceuticals by 4.4% in the 1st quarter. Alliancebernstein L.P. now owns 233,951 shares of the biopharmaceutical company’s stock worth $90,658,000 after acquiring an additional 9,759 shares during the period. Hedge funds and other institutional investors own 67.95% of the company’s stock.

In other news, Director Charles A. Baker sold 2,000 shares of the business’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $450.00, for a total value of $900,000.00. Following the sale, the director now owns 11,000 shares of the company’s stock, valued at $4,950,000. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Sanofi acquired 166,415 shares of the business’s stock in a transaction dated Thursday, August 24th. The stock was acquired at an average cost of $480.93 per share, for a total transaction of $80,033,965.95. The disclosure for this purchase can be found here. Insiders sold a total of 87,968 shares of company stock worth $41,599,948 in the last three months. Company insiders own 10.80% of the company’s stock.

Several research firms have recently issued reports on REGN. Leerink Swann reiterated an “outperform” rating and issued a $493.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, June 13th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 14th. Piper Jaffray Companies boosted their target price on Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the stock an “overweight” rating in a report on Tuesday, June 20th. BMO Capital Markets reissued a “market perform” rating and set a $421.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 21st. Finally, Canaccord Genuity set a $484.00 target price on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, June 20th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $487.26.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded down 0.883% during midday trading on Wednesday, hitting $451.605. The stock had a trading volume of 87,925 shares. The firm has a market cap of $47.89 billion, a P/E ratio of 45.305 and a beta of 1.62. The stock has a 50-day moving average of $460.77 and a 200-day moving average of $451.15. Regeneron Pharmaceuticals, Inc. has a 52 week low of $325.35 and a 52 week high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company’s revenue was up 21.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.82 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.93 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “FUKOKU MUTUAL LIFE INSURANCE Co Continues to Hold Position in Regeneron Pharmaceuticals, Inc. (REGN)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/04/fukoku-mutual-life-insurance-co-continues-to-hold-position-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.